Streetbeat News

Legal

EWW

SPY

U.S. Supreme Court Justice Samuel Alito has extended a temporary pause on a Texas law that permits state law enforcement to arrest individuals suspected of illegally crossing the U.S.-Mexico border. This decision continues to halt the implementation of the law pending further legal review.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 2:23 pm

NVDA

NVIDIA Corporation (NASDAQ:NVDA) shares fell 2% to close at $857.74 on Monday, following a recent 19% gain over the past month and a 78% increase year-to-date. Mizuho analyst Vijay Rakesh maintained a Buy rating on NVIDIA, raising the price target from $850 to $1,000. NVIDIA faces a lawsuit from three authors alleging unauthorized use of their works to train its AI platform. The article also explores how investors can earn monthly income from NVIDIA's dividends, with an annual yield of 0.02%.

Portfolio Pulse from Avi Kapoor

March 12, 2024 | 1:38 pm

GERN

FDA staff reviewers have expressed concerns about Geron's anemia drug Imetelstat, citing substantial risks associated with its treatment. They indicated that it's unclear if the benefits outweigh the risks for the intended population, and patient-reported outcomes do not support the treatment effect of Imetelstat.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 1:38 pm

BA

New Zealand's TAIC seized the black boxes from a LATAM Airlines Boeing 787 after it experienced severe turbulence, injuring over 50 people. The incident adds to Boeing's challenges, already under scrutiny for safety practices following other incidents. The seizure and investigation could impact Boeing's reputation and regulatory scrutiny.

Portfolio Pulse from Benzinga Neuro

March 12, 2024 | 1:30 pm

GNPX

Genprex has been granted a Korean patent for its Reqorsa Immunogene Therapy in combination with PD-1 and PD-L1 antibodies for cancer treatment. This development could enhance Genprex's intellectual property portfolio and potentially boost its position in the global oncology market.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 1:03 pm

PLBY

PLBY Group, Inc. (NASDAQ:PLBY) announced it will restate its Q2 and Q3 2023 financials due to accounting errors related to an impaired Chinese license contract and commission expense adjustments. The restatements are expected to decrease net loss, increase Adjusted EBITDA, decrease total liabilities, with no impact on revenue, cash flows, liquidity, or future operations. The company will report its Q4 and full year 2023 financial results on March 27, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:04 pm

ACI

AMZN

COST

KR

WMT

The FTC's challenge to the Kroger (KR) and Albertsons (ACI) $24.6 billion merger is set for an August trial in Oregon. The FTC, supported by eight states and Washington D.C., argues the merger could harm worker wages and consumer prices. Kroger and Albertsons defend the merger as necessary to compete with giants like Amazon (AMZN), Walmart (WMT), and Costco (COST), proposing investments to address concerns. However, the FTC finds their divestment plan insufficient. KR shares dropped 1.75% following the news.

Portfolio Pulse from Shivani Kumaresan

March 12, 2024 | 11:59 am

NRXP

NRx Pharmaceuticals is considering a reverse stock split to comply with Nasdaq listing requirements. This action may also involve a change in the company's name and CUSIP number. Additionally, the company has hired attorneys to address and prevent naked short positions in its securities.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:57 am

TSLA

Tesla Inc (NASDAQ:TSLA) is enforcing a no-resale clause against Cybertruck owners attempting to sell their vehicles, as evidenced by the company canceling orders and blacklisting a customer named Dennis from Arizona. This action follows reports of Cybertrucks being sold for as much as $250,000. Tesla's motor vehicle agreement prohibits reselling the Cybertruck within a year of delivery without Tesla's written consent, under penalty of $50,000 or more.

Portfolio Pulse from Anan Ashraf

March 12, 2024 | 11:38 am

IMVT

Immunovant has been awarded a U.S. patent for IMVT-1402, a significant development that could enhance the company's intellectual property portfolio and potentially impact its market position.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:32 am